Corrigendum: Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer.

[This corrects the article DOI: 10.3389/fonc.2019.

Optimization of intravoxel incoherent motion (IVIM): variability of parameters measurements using a reduced distribution of b values for breast tumors analysis.

Objectives: This study aimed to examine the variability of intravoxel incoherent motion measurements acquired from reduced distributions of b values for breast tumors analysis.

Materials And Methods: The investigations were carried out on twenty-four patients with diagnosed breast tumors. A conventional unenhanced MRI and various IVIM series preset with different distributions of b values (0-1000 s/mm) were performed.

Monitoring the Early Antiproliferative Effect of the Analgesic-Antitumor Peptide, BmK AGAP on Breast Cancer Using Intravoxel Incoherent Motion With a Reduced Distribution of Four -Values.

The present study aimed to investigate the possibility of using intravoxel incoherent motion (IVIM) diffusion magnetic resonance imaging (MRI) to quantitatively assess the early therapeutic effect of the analgesic-antitumor peptide BmK AGAP on breast cancer and also evaluate the medical value of a reduced distribution of four -values. IVIM diffusion MRI using 10 -values and 4 -values (0-1,000 s/mm) was performed at five different time points on mice bearing xenograft breast tumors treated with BmK AGAP. Variability in , , , and derived from the set of 10 -values and 4 -values was assessed to evaluate the antitumor effect of BmK AGAP on breast tumor.

Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness, and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer.

A scorpion peptide reported to exhibit both analgesic and antitumor activity in animal models may present as an alternative therapeutic agent for breast cancer. We aimed to investigate the effect of antitumor-analgesic peptide (BmK AGAP) on breast cancer cell stemness and epithelial-mesenchymal transition (EMT). We treated MCF-7 and MDA-MB-231 cells with different concentrations of rBmK AGAP and observed that rBmK AGAP inhibited cancer cell stemness, epithelial-mesenchymal transition (EMT), migration, and invasion.